Matrix completes Phase I study of tezacitabine

13 December 2001

Matrix Pharmaceuticals' tezacitabine (FMdC) has been found to begenerally well-tolerated in a Phase I study involving patients with relapsed or refractory acute leukemias. The trial, which enrolled 32 patients (24 with acute myeloid leukemia and eight with acute lymphocytic leukemia), found that the most common drug-related adverse events were fever (48%), skin reactions (28%), chills (24%) and gastrointestinal events (nausea - 21%, diarrhea -24%, constipation -15%).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight